Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

2015130 citationsJournal Articlebronze Open Access

Authors

E. Q. Lee · University of Pittsburgh

David A. Reardon · Central DuPage Hospital

D. Schiff · Harvard University

J. Drappatz · Central DuPage Hospital

Alona Muzikansky · Dana-Farber Brigham Cancer Center

Sean Grimm · Central DuPage Hospital

Andrew D. Norden ·

Abstract

This phase II study of panobinostat and bevacizumab in participants with recurrent GBM did not meet criteria for continued accrual, and the GBM cohort of the study was closed. Although it was reasonably well tolerated, the addition of panobinostat to bevacizumab did not significantly improve PFS6 compared with historical controls of bevacizumab monotherapy in either cohort.

Topics & Keywords

Glioma Diagnosis and Treatment Histone Deacetylase Inhibitors Research Cancer, Hypoxia, and Metabolism

Publication Details

Published in: Neuro-Oncology

Volume 17, Issue 6, pp. 862-867

DOI: 10.1093/neuonc/nou350

Field-Weighted Citation Impact: 7.09

Command Palette

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Authors

Abstract

Topics & Keywords

Publication Details